Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Neovii Biotech
This study is randomized, prospective, double-blind, placebo-controlled, phase 3 study evaluating the prevention of moderate to severe chronic GVHD in patients undergoing bone marrow or peripheral blood stem cell transplantation from matched, unrelated donors for acute leukemia and myelodysplastic syndrome during the first year after transplant.
Patients meeting all the inclusion and none of the exclusion criteria will be randomized (1:1). All patients will receive premedication and study drug 3 days prior to transplantation.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients designated to undergo allogeneic peripheral blood or bone marrow stem cell transplantation following the diagnosis of one of the primary diseases in early or intermediate disease status (i.e., acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome)
Patients with an unrelated HLA-A,-B, -C and -DRBI matched donor
Patients with a Karnofsky Performance Score ≥ 70%
You may not be if
Clinically significant concomitant diseases (i.e., cardiac, pulmonary, renal and CNS)
Bacterial, viral, or fungal infections
Known positive for Hepatitis B surfaces antigen, or Hepatitis C antibody, or who have been tested positive for HIV
Patients with any concurrent malignancy. Cancer treated with curative intent \< 5 years previously will not be allowed except for patients with resected basal cell carcinoma or treated cervical carcinoma in situ
Known contraindications to the administration of rabbit immunoglobulin antibodies
Hypersensitivity to methylprednisolone, tacrolimus, methotrexate or any excipients contains in these products